Skip header and navigation

Refine By

5 records – page 1 of 1.

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

https://arctichealth.org/en/permalink/ahliterature272653
Source
Leuk Lymphoma. 2015 Jul;56(7):2005-12
Publication Type
Article
Date
Jul-2015
Author
Karen Juul Mylam
Lale Kostakoglu
Martin Hutchings
Morton Coleman
Dominick Lamonica
Myron S Czuczman
Louis F Diehl
Anne L Nielsen
Paw Jensen
Annika Loft
Helle W Hendel
Victor Iyer
Sirpa Leppä
Sirkku Jyrkkiö
Harald Holte
Mikael Eriksson
Dorte Gillstrøm
Per B Hansen
Marko Seppänen
Karin Hjorthaug
Peter de Nully Brown
Lars M Pedersen
Source
Leuk Lymphoma. 2015 Jul;56(7):2005-12
Date
Jul-2015
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Denmark
Female
Finland
Fluorodeoxyglucose F18 - pharmacokinetics
Follow-Up Studies
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy - mortality - pathology
Male
Middle Aged
Multimodal Imaging
Neoplasm Staging
Norway
Positron-Emission Tomography - methods
Prognosis
Prospective Studies
Radiopharmaceuticals - pharmacokinetics
Survival Rate
Sweden
Tissue Distribution
Tomography, X-Ray Computed - methods
United States
Young Adult
Abstract
We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.
PubMed ID
25330442 View in PubMed
Less detail

Clinical importance of re-interpretation of PET/CT scanning in patients referred to a tertiary care medical centre.

https://arctichealth.org/en/permalink/ahliterature281051
Source
Clin Physiol Funct Imaging. 2017 Mar;37(2):143-147
Publication Type
Article
Date
Mar-2017
Author
Johan Löfgren
Annika Loft
Vinicius Araújo Barbosa de Lima
Kell Østerlind
Eric von Benzon
Liselotte Højgaard
Source
Clin Physiol Funct Imaging. 2017 Mar;37(2):143-147
Date
Mar-2017
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Denmark
Double-Blind Method
Female
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Neoplasms - diagnostic imaging
Observer Variation
Positron Emission Tomography Computed Tomography
Predictive value of tests
Prospective Studies
Radiopharmaceuticals
Referral and Consultation
Reproducibility of Results
Tertiary Care Centers
Young Adult
Abstract
To evaluate, in a controlled prospective manner with double-blind read, whether there are differences in interpretations of PET/CT scans at our tertiary medical centre, Rigshospitalet, compared to the external hospitals.
Ninety consecutive patients referred to our department who had an external F-18-FDG PET/CT scan were included. Only information that had been available at the time of the initial reading at the external hospital was available at re-interpretation. Teams with one radiologist and one nuclear medicine physician working side by side performed the re-interpretation in consensus. Two oncologists subsequently and independently compared the original reports with the re-interpretation reports. In case of 'major discordance', the oncologists assessed the respective reports validities.
The interpretations were graded as 'accordant' in 43 patients (48%), 'minor discordance' in 30 patients (33%) and 'major discordance' in 17 patients (19%). In 11 (65%) of the 17 cases graded as 'major discordance', it was possible to determine which report that was most correct. In 9 of these 11 cases (82%), the re-interpretation was most correct; in one case, the original report and in another case, both interpretations were incorrect.
Major discordant interpretations were frequent [19% (17 of 90 cases)]. In those cases where follow-up could assess the validity, the re-interpretation at Rigshospitalet was most correct in 9 of 11 cases (82%), indicating that there is a difference in expertise in interpreting PET/CT at a tertiary referral hospital compared to primary local hospitals.
PubMed ID
26211508 View in PubMed
Less detail

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.

https://arctichealth.org/en/permalink/ahliterature269527
Source
Am J Hematol. 2015 Nov;90(11):1041-6
Publication Type
Article
Date
Nov-2015
Author
Tarec Christoffer El-Galaly
Diego Villa
Musa Alzahrani
Jakob Werner Hansen
Laurie H Sehn
Don Wilson
Peter de Nully Brown
Annika Loft
Victor Iyer
Hans Erik Johnsen
Kerry J Savage
Joseph M Connors
Martin Hutchings
Source
Am J Hematol. 2015 Nov;90(11):1041-6
Date
Nov-2015
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow - pathology
Canada
Cyclophosphamide
Denmark
Doxorubicin
Female
Fluorodeoxyglucose F18
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis - drug therapy - mortality - pathology
Male
Middle Aged
Neoplasm Staging
Ovary - pathology
Pleura - pathology
Positron-Emission Tomography
Prednisone
Prognosis
Retrospective Studies
Survival Analysis
Tomography, X-Ray Computed
Vincristine
Abstract
18F-fluorodeoxyglucose PET/CT (PET/CT) is the current state-of-the-art in the staging of diffuse large B-cell lymphoma (DLBCL) and has a high sensitivity for extranodal involvement. Therefore, reassessment of extranodal involvement and the current prognostic indices in the PET/CT era is warranted. We screened patients with newly diagnosed DLBCL seen at the academic centers of Aalborg, Copenhagen, and British Columbia for eligibility. Patients that had been staged with PET/CT and treated with R-CHOP(-like) 1(st) line treatment were retrospectively included. In total 443 patients met the inclusion criteria. With a median follow-up of 2.4 years, the 3-year overall (OS) and progression-free survival (PFS) were 73% and 69%, respectively. The Ann Arbor classification had no prognostic impact in itself with the exception of stage IV disease (HR 2.14 for PFS, P2 extranodal sites, including HR 7.81 (P?3 sites. Bone/bone marrow involvement was the most commonly involved extranodal site identified by PET/CT (29%) and was associated with an inferior PFS and OS. The IPI, R-IPI, and NCCN-IPI were predictive of PFS and OS, and the two latter could identify a very good prognostic subgroup with 3-year PFS and OS of 100%. PET/CT-ascertained extranodal involvement in DLBCL is common and involvement of >2 extranodal sites is associated with a dismal outcome. The IPI, R-IPI, and NCCN-IPI predict outcome with high accuracy.
PubMed ID
26260224 View in PubMed
Less detail

PET/MRI in cancer patients: first experiences and vision from Copenhagen.

https://arctichealth.org/en/permalink/ahliterature117816
Source
MAGMA. 2013 Feb;26(1):37-47
Publication Type
Article
Date
Feb-2013
Author
Andreas Kjær
Annika Loft
Ian Law
Anne Kiil Berthelsen
Lise Borgwardt
Johan Löfgren
Camilla Bardram Johnbeck
Adam Espe Hansen
Sune Keller
Søren Holm
Liselotte Højgaard
Author Affiliation
Department of Clinical Physiology, Nuclear Medicine & PET, University of Copenhagen, KF-4012 Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. akjaer@sund.ku.dk
Source
MAGMA. 2013 Feb;26(1):37-47
Date
Feb-2013
Language
English
Publication Type
Article
Keywords
Adult
Child
Contrast Media - diagnostic use
Denmark
Female
Humans
Magnetic Resonance Imaging - instrumentation - methods
Male
Middle Aged
Neoplasms - diagnosis - radionuclide imaging
Positron-Emission Tomography - instrumentation - methods
Radiopharmaceuticals - diagnostic use
Sensitivity and specificity
Abstract
Combined PET/MRI systems are now commercially available and are expected to change the medical imaging field by providing combined anato-metabolic image information. We believe this will be of particular relevance in imaging of cancer patients. At the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet in Copenhagen we installed an integrated PET/MRI in December 2011. Here, we describe our first clinical PET/MR cases and discuss some of the areas within oncology where we envision promising future application of integrated PET/MR imaging in clinical routine. Cases described include brain tumors, pediatric oncology as well as lung, abdominal and pelvic cancer. In general the cases show that PET/MRI performs well in all these types of cancer when compared to PET/CT. However, future large-scale clinical studies are needed to establish when to use PET/MRI. We envision that PET/MRI in oncology will prove to become a valuable addition to PET/CT in diagnosing, tailoring and monitoring cancer therapy in selected patient populations.
PubMed ID
23266511 View in PubMed
Less detail

Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.

https://arctichealth.org/en/permalink/ahliterature266857
Source
Medicine (Baltimore). 2015 Jul;94(28):e1142
Publication Type
Article
Date
Jul-2015
Author
Kim Francis Andersen
Hanna Maria Fuglo
Sine Hvid Rasmussen
Michael Mork Petersen
Annika Loft
Source
Medicine (Baltimore). 2015 Jul;94(28):e1142
Date
Jul-2015
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Bone Neoplasms - metabolism - mortality - radionuclide imaging
Child
Denmark - epidemiology
Female
Fluorodeoxyglucose F18 - diagnostic use
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
ROC Curve
Retrospective Studies
Sarcoma - metabolism - mortality - radionuclide imaging
Soft Tissue Neoplasms - metabolism - mortality - radionuclide imaging
Young Adult
Abstract
To assess the prognostic value of primary tumor metabolic activity in patients with high-grade bone sarcomas (BS) or soft tissue sarcomas (STS) using F-18 FDG PET/CT. A single-site, retrospective study including 92 patients with high-grade BS or STS. Pretreatment F-18 FDG PET/CT scan was performed. Clinical data were registered. Accuracy of maximum standardized uptake value of primary tumor (SUVmax) and tumor-to-background (T/B) uptake ratio as prognostic variables and identification of cut-off values to group patients were determined. Kaplan-Meier survival estimates and log-rank test were used to compare survival distributions. Prognostic variables were assessed using Cox proportional hazards regression analysis. Forty-one of 92 patients died during follow-up (45%). Average survival was 6.5 years (95% CI 5.8-7.3 years) and probability of 5-year survival was 52%. Accuracy of SUVmax and T/B uptake ratio as prognostic variables in all patients and during subgroup analysis of patients with STS was significant. No significant results for AUCs were registered in patients with BS. Surgery was independently prognostic for survival throughout multivariate regression analysis of all patients (P?=?0.001, HR 3.84) and subgroup analysis (BS: P?=?0.02, HR 11.62; STS: P?=?0.005, HR 4.13). SUVmax was significant as prognostic variable in all patients (P?=?0.02, HR 3.66) and in patients with STS (P?=?0.007, HR 3.75). No significant results were demonstrated for T/B uptake ratio. Estimation of primary tumor metabolic activity with pretherapeutic SUVmax using F-18 FDG PET/CT demonstrates independent properties beyond histologic grading for prediction of survival in patients with high-grade STS, but not with high-grade BS.
PubMed ID
26181552 View in PubMed
Less detail